August 2012
-
Danish pharma company Union Therapeutics has entered into an agreement with TFF Pharmaceuticals for an option to license TFF’s dry powder niclosamide, the companies announced. The deal includes potential inhaled and oral formulations of niclosamide… Read more . . .
-
Aerosol testing company Proveris Scientific has announced two new appointments: Joseph Werbeck rejoins the company as Senior Director of Technical Service and Mohamed Eldam joins Proveris as Applications Chemist. Werbeck, who will report to VP… Read more . . .
-
AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of… Read more . . .
-
TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to “to accelerate the expansion of the company’s internal development portfolio beyond its programs for… Read more . . .
-
Biohaven Pharmaceutical will receive up to $250 million from Royalty Pharma on closing of a deal to fund development of its zavegepant (formerly vazegepant) calcitonin gene-related peptide (CGRP) receptor antagonist program, which includes intranasal zavegepant,… Read more . . .
-
An RA Capital Management company called Aerovate Therapeutics has raised $72.6 million in Series A financing for development of its AV-101 dry powder imatinib for the treatment of pulmonary arterial hypertension (PAH), the company said.… Read more . . .
-
Three weeks after recalling numerous lots of desmopressin nasal sprays in the UK and a number of other countries, Ferring has issued a recall of all lots of DDAVP 10 mcg/0.1ml, Stimate 1.5 mg/ml, and… Read more . . .
-
A Phase 3 trial of Levo Therapeutics’ LV-101 intranasal carbetocin in children with Prader-Willi Syndrome (PWS) failed to meet its primary endpoint, the company said. Enrollment in the study, which began in 2018, was stopped… Read more . . .
-
The FDA has cleared an IND for NeuroRx to conduct a clinical trial of an inhaled formulation of its RLF-100 aviptadil in patients with moderate or severe COVID-19, the company said. NeuroRx recently announced that… Read more . . .
-
Bryn Pharma said that it has raised $11 million in an extension of the financing that raised over $17 million in October 2019 to fund activities related to its BRYN-NDS1C epinephrine nasal spray candidate, which is… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.